ArticleJournal of pain research2026
Efficacy and Central Mechanism of Shexiang Zhuifeng Analgesic Plaster Combined with Transcranial Direct Current Stimulation in the Treatment of Knee Osteoarthritis: Study Protocol for a Randomized Controlled Trial.
Article in Journal of pain research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Knee osteoarthritis (KOA) is a chronic pain disorder accompanied by central sensitization, and its treatment remains challenging. While Shexiang Zhuifeng Analgesic Plaster (SZAP) has been shown to effectively alleviate peripheral inflammation and pain, transcranial direct current stimulation (tDCS) can modulate cortical excitability and influence central pain processing. The combination of these two interventions may produce a synergistic "peripheral-central" analgesic effect. This study aims to evaluate the efficacy of this combined approach and utilize neuroimaging techniques to elucidate its underlying central neural mechanisms. Methods: This randomized, controlled, double-blind study will enroll 48 patients with KOA. They will be equally divided into a treatment group and a control group. The treatment group will receive SZAP combined with tDCS, while the control group will receive SZAP combined with sham tDCS. SZAP will be administered once daily, five days per week, and tDCS will be administered three times per week (alternate days) for four weeks. All outcome measures will be measured at baseline and after four weeks of intervention. Efficacy outcomes include visual analogue scale pain scores and the Western Ontario and McMaster Universities Osteoarthritis Index score. The mechanistic analysis focuses on electroencephalogram power spectral density and functional connectivity analysis. Discussion: This study will innovatively combine SZAP with tDCS for the treatment of KOA, based on a comprehensive peripheral and central intervention approach. The study will explore the combined efficacy and analyze its potential central mechanisms. This will not only provide valuable clinical treatment approaches for KOA but will also deepen our understanding of the disease's mechanisms. Trial Registration: ITMCTR (registration number: ITMCTR2025002557), registered on December 27, 2025, https://itmctr.ccebtcm.org.cn/mgt/project/view/2004717515376295936.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.